Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Radhakrishnan, Raghu | |
dc.contributor.author | Crane, Hannah L. | |
dc.contributor.author | Daigneault, Marc | |
dc.contributor.author | Ram Padam, Kanaka Sai | |
dc.contributor.author | Hunter, K.D. (Keith) | |
dc.date.accessioned | 2022-02-09T12:06:04Z | |
dc.date.available | 2022-02-09T12:06:04Z | |
dc.date.issued | 2021-08-12 | |
dc.description | ADDITIONAL FILE 1: Figure S1: Expression of cRBP1 under AZA-C and ATRA treatment as assessed by qPCR. The pattern of expression in D19 is very similar to that in D34. | en_ZA |
dc.description | ADDITIONAL FILE 2: Original blots and gels - all figures revised | en_ZA |
dc.description.abstract | Loss of RARβ2 expression by promoter methylation is an early event in oral carcinogenesis. Understanding the mechanisms and consequences of RARβ loss may aid in understanding the disappointing results of retinoid chemoprevention trials. This study aimed to describe the effects of all-trans retinoic acid (ATRA) and the de-methylating agent 5-Aza-2' deoxycytidine (5-AZA-CdR) on a panel of immortal potentially malignant oral lesion (PMOL) cell cultures. RARβ expression was assessed in PMOL tissues by immunohistochemistry. Cells were treated with ATRA ± 5-AZA-CdR, and the effects on the cell cycle and senescence were assessed. In PMOL tissues, RARβ expression was variable, but lower in biopsies which gave rise to immortal cell cultures. Treatment of iPMOL cells with ATRA resulted in little change in RARβ expression, but the addition of 5-AZA-CdR resulted in significant increases. The effects on the cell cycle and senescence were variable and may be related to 5-AZA-CdR, as this has wider effects on the cell cycle. Overall, the response of iPMOL cells to ATRA and 5-AZA-CdR treatment was variable and is dependent on several factors, including RARβ-promoter methylation. These findings may help to explain the lack of consistent effect of retinoids in PMOLs seen in chemoprevention trials. | en_ZA |
dc.description.department | Oral Pathology and Oral Biology | en_ZA |
dc.description.librarian | am2022 | en_ZA |
dc.description.sponsorship | This research was funded by the European Commission FP7 Marie Curie Incoming Fellowship, grant number PIIF-GA-2012-327300. | en_ZA |
dc.description.sponsorship | The European Commission FP7 Marie Curie Incoming Fellowship | en_ZA |
dc.description.uri | https://www.mdpi.com/journal/cancers | en_ZA |
dc.identifier.citation | Radhakrishnan, R.; Crane, H.L.; Daigneault, M.; Padam, K.S.R.; Hunter, K.D. Rarβ expression in keratinocytes from potentially malignant oral lesions: the functional consequences of re-expression by de-methylating agents. Cancers 2021, 13, 4064. https://DOI.org/ 10.3390/cancers13164064. | en_ZA |
dc.identifier.issn | 2072-6694 (online) | |
dc.identifier.other | 10.3390/ cancers13164064 | |
dc.identifier.uri | http://hdl.handle.net/2263/83733 | |
dc.language.iso | en | en_ZA |
dc.publisher | MDPI | en_ZA |
dc.rights | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_ZA |
dc.subject | Oral cancer | en_ZA |
dc.subject | Oral potentially malignant lesions | en_ZA |
dc.subject | Retinoids | en_ZA |
dc.subject | Chemoprevention | en_ZA |
dc.subject | All-trans retinoic acid (ATRA) | en_ZA |
dc.subject | RARβ2 | en_ZA |
dc.subject | Potentially malignant oral lesion (PMOL) | en_ZA |
dc.subject | De-methylating agent 5-Aza-2′ deoxycytidine (5-AZA-CdR) | en_ZA |
dc.title | Rarβ expression in keratinocytes from potentially malignant oral lesions : the functional consequences of re-expression by de-methylating agents | en_ZA |
dc.type | Article | en_ZA |